News Center

位置：

Honors Announcement

Group News

Media Reports

Guangxiang Pharmaceutical of Shisiyao Group Has Been Recognized as the Cangzhou City Technology Innovation Center

Category:

Honors Announcement

发布时间：2021-03-24

【概要描述】 Recently, Hebei Guangxiang Pharmaceutical Co., Ltd. of Shisiyao Group was recognized by the Cangzhou Municipal Science and Technology Bureau as the Cangzhou Fluid-Form API Technology Innovation Center.

Recently, Hebei Guangxiang Pharmaceutical Co., Ltd. of Shisiyao Group was recognized by the Cangzhou Municipal Science and Technology Bureau as the Cangzhou Fluid-Process API Technology Innovation Center. This marks another innovation-driven technological platform established by the company, following its 2020 designation as a provincial-level R&D institution for industrial enterprises, a postdoctoral research workstation, and a provincial engineering research center for microreactor-based continuous synthesis of APIs.

▲ Shisiyao Group’s Guangxiang Pharmaceutical adheres to the concept of green development and strives to set a benchmark for high-quality growth. The photo shows the exterior of the factory premises.

Guangxiang Pharmaceutical is a large-scale domestic API industrialization base established in the Bohai New Area through investment by Shisiyao Group. Leveraging the opportunities presented by the coordinated development of the Beijing–Tianjin–Hebei region, the Group has implemented an “one core, two wings” development strategy, strategically positioning itself at the upstream end of the industry chain. The facility specializes in the production, R&D, and export of both bulk APIs—such as caffeine, metronidazole, theophylline, aminophylline, and nifedipine—and high-value-added specialty APIs—including arbidol, pentoxifylline, rosuvastatin calcium, and pitavastatin calcium—comprising dozens of such products in total.
Since the commencement of construction on the Guangxiang Pharmaceutical Project of Shisiyao Group in October 2017, the company has leveraged its robust R&D and innovation capabilities to focus on the independent development of specialty and high-end active pharmaceutical ingredients (APIs), as well as on breakthroughs in key API synthesis technologies. Efforts have been continuously intensified to accelerate the efficiency of new API-plus-formulation product development and to drive further innovation in API synthesis processes, with a strong emphasis on raising quality standards, reducing material, energy, and environmental consumption, and thereby supporting the enterprise’s innovative, green, and high-quality development.

▲ Researchers at Guangxiang Pharmaceutical, a subsidiary of Shisi Pharmaceutical Group, are conducting experiments on a new product.

The “Cangzhou Fluid-Phase Active Pharmaceutical Ingredient Technology Innovation Center” being established this time primarily leverages microchannel reactor technology to intensify key steps in existing conventional batch synthesis routes, transitioning to continuous processing to facilitate the industrialization of green chemistry, enhance reaction efficiency, and reduce production costs. At the same time, by utilizing the Innovation Center as a platform, the initiative is actively collaborating with numerous domestic research institutes to jointly establish joint R&D institutions, accelerate the cultivation of high-level innovative talent and promote technological exchange, and continuously strengthen independent innovation capabilities and standards.
According to reports, in order to implement the Cangzhou City Three-Year Action Plan for Scientific and Technological Innovation and in accordance with the Measures for the Establishment and Administration of Cangzhou City Technical Innovation Centers, the Cangzhou Municipal Science and Technology Bureau organized the 2020 municipal-level technical innovation center accreditation process. Following preliminary review, expert evaluation, deliberation at the Director’s Office Meeting, and public announcement, a total of 27 entities were newly accredited as Cangzhou municipal-level technical innovation centers, including Hebei Guangxiang Pharmaceutical Co., Ltd. of Shisiyao Group, designated as the “Cangzhou Fluid-Form Raw Material Pharmaceutical Technical Innovation Center.”

▲ Employees at the production workshop of Guangxiang Pharmaceutical, part of Shisiyao Group, operate production equipment to manufacture active pharmaceutical ingredients.

In accordance with the relevant requirements of the “Administrative Measures for the Establishment and Management of Technological Innovation Centers in Cangzhou City,” all implementing entities are required to establish and manage their respective technological innovation centers, proactively accept oversight and performance assessments by the competent authorities, increase R&D investment, actively engage in the research, development, and commercialization of new technologies and products, cultivate and attract innovative talent and teams, and provide technical support for the innovative development of enterprises and the industry.

Keywords:

Bromhexine Hydrochloride Injection Approved, Adding Another “Dark Horse” to Shijiazhuang Sihua Pharmaceutical’s Small-Volume Injectable Portfolio

Shijiazhuang Sihua Pharmaceutical’s Metronidazole and Sodium Chloride Injection Has Passed the Consistency Evaluation

Bromhexine Hydrochloride Injection Approved, Adding Another “Dark Horse” to Shijiazhuang Sihua Pharmaceutical’s Small-Volume Injectable Portfolio

Shijiazhuang Sihua Pharmaceutical’s Metronidazole and Sodium Chloride Injection Has Passed the Consistency Evaluation